New guidelines from GMC and Nursing and Midwifery Council
Combining their immunotherapies
Paying $200 million upfront for US/Australian group
Could be used in clinical trials to generate continuous data
Will focus on access to its therapies for viral hepatitis and cancers in women such as breast, cervical and ovarian
Follows CMO Briggs Morrison out of the company
Had been rejected by the agency last year
Satisfies antitrust regulators following Novartis tie-up
Britain lags behind other countries in terms of cancer survival - one of the big reasons is late diagnosis
Could treat patients with just a single $1 dose but very early-stage
Gets access to double-chin therapy Kybella
Exp. Medical Reps and trainees. KAMs; eDetailing Reps Nationwide Opportunities
Click here to apply now!
2 x Respiratory Med Rep!
Click here to apply!
Nurse Advisor Roles
Click here to apply now
Find your next position today!
Click here to apply
Contracts and Pricing Manager
No running polls, please check backsoon.
Increase your knowledge. Browse the Pf Archive.
Read Pf now
Looking to make a move? Find your next job here.
click here to createan account
Need career advice? Visit our Career Centre.